May 17, 2017 / 11:21 AM / 2 months ago

BRIEF-Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial

1 Min Read

May 17 (Reuters) - Omeros Corp

* Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial

* Omeros Corp - additional positive results support rapid advancement to phase 3 trial

* Omeros Corp - consistent with all other OMS721 clinical trials, no significant safety concerns have been observed

* Omeros Corp - most commonly reported adverse events in trial are fatigue and anemia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below